Search

Displaying results 9561 - 9570 of 10000 in total
  1. Drug

    PF-06459988

    go.drugbank.com/drugs/DB14768
    Investigational

    PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

  2. Drug

    Etamicastat

    go.drugbank.com/drugs/DB15288
    Investigational

    Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).

  3. Drug

    Bevifimod

    go.drugbank.com/drugs/DB15301
    Investigational

    Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).

  4. Drug

    ALT-801

    go.drugbank.com/drugs/DB15386
    Investigational

    ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).

  5. Drug

    Parathyroid Hormone-Related Protein 1-36

    go.drugbank.com/drugs/DB16278
    Investigational

    Parathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis).

  6. Drug

    YS-ON-001

    go.drugbank.com/drugs/DB17291
    Investigational

    YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).

  7. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  8. Drug

    Prifinium

    go.drugbank.com/drugs/DB13254
    Experimental

    Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome [A175027].

  9. Drug

    Arlocabtagene autoleucel

    go.drugbank.com/drugs/DB24024
    Investigational

    Arlocabtagene Autoleucel is under investigation in clinical trial NCT06297226 (Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or … Arlocabtagene Autoleucel is a biologic drug.

  10. Drug

    Pepinemab

    go.drugbank.com/drugs/DB15155
    Investigational

    Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).